Chlorpromazine, a landmark medication in the history of psychiatry, is a potent typical antipsychotic belonging to the phenothiazine class, primarily utilized for the treatment of schizophrenia and other psychotic disorders by acting as a dopamine receptor antagonist. Its discovery represents a psychopharmacological revolution that began in December 1950 when chemists at the French Rhône-Poulenc laboratories, while researching antihistamines, synthesized the compound. Initially introduced in the early 1950s as an adjunct to anesthesia for its ability to induce artificial hibernation and reduce surgical shock, its profound calming effects on agitated and psychotic patients were soon recognized by researchers like Henri Laborit and later validated in clinical trials by Jean Delay and Pierre Deniker in 1952. By the mid-1950s, its global adoption transformed psychiatric care, moving the field away from older, often more invasive treatments like lobotomy or electroconvulsive therapy toward a more effective and humane pharmacological approach, ultimately establishing the foundation for modern neuropsychopharmacology.
